Becton, Dickinson and Company (BDX) Set to Announce Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Becton, Dickinson and Company to post earnings of $2.96 per share for the quarter. Becton, Dickinson and Company has set its FY24 guidance at $12.82-13.86 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same period in the prior year, the firm posted $2.98 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Up 0.8 %

BDX stock opened at $233.50 on Tuesday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The firm has a market cap of $67.46 billion, a PE ratio of 55.33, a PEG ratio of 1.91 and a beta of 0.43. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32. The company has a fifty day simple moving average of $239.10 and a 200 day simple moving average of $240.93.

Insiders Place Their Bets

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BDX. Raymond James boosted their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Barclays upped their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.